VIVS: Organovo Holdings Inc. Price to Sales

Symbol and logo of brand Organovo Holdings, Inc. (VIVS)

VivoSim Labs Inc (VIVS) is scaling revenue through AI modeling and contracts with pharmaceutical giants. The company is implementing 3D bioprinting to optimize clinical trials, maintaining resilience to market cycles through innovation. This P/S chart allows for a valuation of the business relative to revenue, while the 21.00 mark reflects the current state of quotes compared to historical norms.

VIVS (Organovo) P/S Multiple history from 04/25/2025 to 11/13/2026

Analytical breakdowns for Organovo Holdings Inc. (VIVS)

- market price and analyst price targets:
Stock Quotes Organovo Holdings|VIVS - Analyst Consensus Forecast
- market capitalization information:
Market Value Organovo Holdings Inc.|VIVS - Enterprise Value
- shareholders' equity book value data:
Equity per Share Organovo|VIVS - Book Capitalization|Market Capitalization to Book Value organovo.com|VIVS - Company Total Assets
- debt obligations and liquidity statistics:
Total Debt to Equity Ratio VivoSim Labs Inc|VIVS - Long-Term Debt to Capital|Short-Term Debt to Capital VivoSim Labs|VIVS - Company Debts|Debt to Book Capitalization Ratio Organovo Holdings Inc.|VIVS - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Organovo|Immediate Liquidity organovo.com
- net income and valuation multiples indicators:
VIVS - Company Net Income|Projected Net Profit VivoSim Labs Inc|VIVS - Price to Earnings Ratio|Forward P/E Multiple Organovo|VIVS - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Organovo Holdings Inc.|VIVS - Profit before payment of interest, taxes and amortization|Earnings per one share for the last 12 months Organovo|VIVS - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months organovo.com|VIVS - Earnings growth in current year|Expected net earnings per share growth next year VivoSim Labs Inc
- issuer revenue and sales details:
VIVS - Company Revenue|Company Revenue Forecast Organovo Holdings Inc.|VIVS - Market Cap to Revenue|Price to Expected Revenue Ratio Organovo Holdings Inc.
Fundamental company analysis:organovo.com VIVS
Original product of Organovo Holdings Inc.

VivoSim Labs Inc (VIVS) monetizes innovations in 3D bioprinting of tissues for pharmaceutical testing, making revenue a key value driver. By analyzing the price-to-sales ratio, an investor determines the market value of every dollar of sales, assessing the market's willingness to pay a premium for the company's technological superiority, while the daily price chart allows for tracking the real-time valuation of the business without quarterly delays.

Who VivoSim Labs Inc competes with

Market Cap to Revenue abbott.com ABT|P/S Multiple TMO (Thermo Fisher)|GE HealthCare Technologies Inc. (GEHC) - Price to Sales|Mettler-Toledo International Inc. - P/S Multiple|WAT (Waters Technologies) - Market Cap to Revenue Ratio|TECH: P/S Multiple|BRKR - Price-to-Revenue Coefficient|AZTA (Azenta) - P/S Multiple|Market Cap to Revenue Varex Imaging Corp (VREX)|P/S Multiple SMLR|P/S Multiple Butterfly Corp (BFLY)|Price-to-Revenue Ratio Mesa Laboratories, Inc. MLAB|quantum-si.com - Price-to-Revenue Ratio|NNOX: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio QTRX (Quanterix Corp.)|MASS: P/S Multiple|Price to Sales CapsoVision (CV)|Price-to-Revenue Ratio MaxCyte, Inc.|RPID - Price-to-Revenue Multiple|Market Cap to Revenue SEER (Seer)|P/S Multiple Hyperfine Inc (HYPR)|P/S Multiple FONR (FONAR Corp)|Price-to-Revenue Coefficient Daxor Corp (DXR)|MDAI - Price-to-Revenue Ratio|Price-to-Sales Ratio ACON|akoyabio.com (AKYA) - Price-to-Revenue Ratio|Market Cap to Revenue ThermoGenesis Holdings, Inc.|TLIS (Talis Biomedical Corp.) - P/S Multiple|Price to Sales T2 Biosystems Inc TTOO